These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 25019624

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Transition to adult rheumatology care is necessary to maintain DMARD therapy in young people with juvenile idiopathic arthritis.
    Luque Ramos A, Hoffmann F, Albrecht K, Klotsche J, Zink A, Minden K.
    Semin Arthritis Rheum; 2017 Oct; 47(2):269-275. PubMed ID: 28583690
    [Abstract] [Full Text] [Related]

  • 3. Importance of pediatric rheumatologists and transitional care for juvenile idiopathic arthritis-associated uveitis: a retrospective series of 9 cases.
    Yamazaki S, Shimbo A, Akutsu Y, Takase H, Morio T, Mori M.
    Pediatr Rheumatol Online J; 2020 Mar 23; 18(1):26. PubMed ID: 32293465
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Impact of Antiinflammatory Treatment on the Onset of Uveitis in Juvenile Idiopathic Arthritis: Longitudinal Analysis From a Nationwide Pediatric Rheumatology Database.
    Tappeiner C, Schenck S, Niewerth M, Heiligenhaus A, Minden K, Klotsche J.
    Arthritis Care Res (Hoboken); 2016 Jan 23; 68(1):46-54. PubMed ID: 26212111
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Access to pediatric rheumatology care for Juvenile Idiopathic Arthritis in the United Arab Emirates.
    Khawaja K, Al-Maini M.
    Pediatr Rheumatol Online J; 2017 May 16; 15(1):41. PubMed ID: 28511684
    [Abstract] [Full Text] [Related]

  • 13. Outcome of transition phase patients with juvenile idiopathic arthritis.
    Relas H, Luosujärvi R, Kosola S.
    Mod Rheumatol; 2018 Sep 16; 28(5):832-837. PubMed ID: 29251024
    [Abstract] [Full Text] [Related]

  • 14. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort.
    Guzman J, Oen K, Tucker LB, Huber AM, Shiff N, Boire G, Scuccimarri R, Berard R, Tse SM, Morishita K, Stringer E, Johnson N, Levy DM, Duffy KW, Cabral DA, Rosenberg AM, Larché M, Dancey P, Petty RE, Laxer RM, Silverman E, Miettunen P, Chetaille AL, Haddad E, Houghton K, Spiegel L, Turvey SE, Schmeling H, Lang B, Ellsworth J, Ramsey S, Bruns A, Campillo S, Benseler S, Chédeville G, Schneider R, Yeung R, Duffy CM, ReACCh-Out investigators.
    Ann Rheum Dis; 2015 Oct 16; 74(10):1854-60. PubMed ID: 24842571
    [Abstract] [Full Text] [Related]

  • 15. Effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt.
    Mourão AF, Santos MJ, Melo Gomes JA, Martins FM, Mendonça SC, Oliveira Ramos F, Fernandes S, Salgado M, Guedes M, Carvalho S, Costa JA, Brito I, Duarte C, Furtado C, Lopes A, Rodrigues A, Sequeira G, Branco JC, Fonseca JE, Canhão H.
    Rheumatology (Oxford); 2016 Apr 16; 55(4):697-703. PubMed ID: 26672905
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Proposal for juvenile idiopathic arthritis guidance on diagnosis and treatment for primary care pediatricians and nonpediatric rheumatologists (2007).
    Yokota S, Mori M, Imagawa T, Takei S, Murata T, Tomiita M, Ito Y, Fujikawa S.
    Mod Rheumatol; 2007 Apr 16; 17(5):353-63. PubMed ID: 17929125
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Clinical features and characteristics of uveitis associated with juvenile idiopathic arthritis in Japan: first report of the pediatric rheumatology association of Japan (PRAJ).
    Yasumura J, Yashiro M, Okamoto N, Shabana K, Umebayashi H, Iwata N, Okura Y, Kubota T, Shimizu M, Tomiita M, Nakagishi Y, Nishimura K, Hara R, Mizuta M, Yasumi T, Yamaide F, Wakiguchi H, Kobayashi M, Mori M.
    Pediatr Rheumatol Online J; 2019 Apr 11; 17(1):15. PubMed ID: 30975163
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
    Schmeling H, Minden K, Foeldvari I, Ganser G, Hospach T, Horneff G.
    Arthritis Rheumatol; 2014 Sep 11; 66(9):2580-9. PubMed ID: 24942886
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.